News
Resources
Blog
Sites
Tim McClung Tim is a director of policy & research at PhRMA.
Recent Posts
Biopharmaceutical manufacturing companies continue to expand their economic footprint across the United States
By Tim McClung | May 24, 2023
Before 2020, the importance of robust and resilient supply chains and how they can affect access to life-saving treatments probably wasn’t top of mind for many outside the biopharmaceutical industry....
Read More
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
By Tim McClung | July 18, 2022
PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for a...
Read More
Biopharmaceutical industry drives economic growth in all 50 states
By Tim McClung | March 14, 2022
The innovative biopharmaceutical industry has long been a significant driver of the nation’s economic growth and a key contributor to state and regional economies. A new report from TEConomy Partners...
Read More
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
By Tim McClung | November 1, 2021
A new report from NDP Analytics showcases how innovation is the lifeblood of economic growth in the United States and that intellectual property (IP) protections are a crucial driver for high rates...
Read More
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
By Tim McClung | July 22, 2021
PhRMA member companies’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad...
Read More
PhRMA member companies invested $83 billion in research and development last year
By Tim McClung | September 10, 2020
PhRMA member companies invested $83 billion in research and development (R&D) in 2019, the highest level of investment on record, according to the 2020 PhRMA member annual survey. Over the past two...
Read More
PhRMA member companies invested nearly $80 billion in R&D last year
By Tim McClung | July 18, 2019
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the 2019 PhRMA member annual survey.
Read More
New Report: Advanced manufacturing powering innovative biopharmaceuticals
By Tim McClung | May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...
Read More
Biopharmaceutical venture capital is spurring innovation and economic growth
By Tim McClung | February 11, 2019
The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...
Read More
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
By Tim McClung | August 9, 2018
PhRMA member companies invested $71.4 billion in research and development (R&D) in 2017, the highest level of investment on record, according to the 2018 PhRMA member annual survey, released in...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
